Physicians' Academy for Cardiovascular Education

Kidney disease & CVD

Follow the news, literature, and elearning on new developments in the management of Kidney disease and CVD

Looking beyond diabetes: The role of SGLT2i and MRAs in cardiorenal disease

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD

New perspectives in managing heart failure and hyperkalemia – The cardiorenal angle

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD & Prof. Austin G. Stack, MD

Reducing morbidity and mortality in patients with CKD and T2DM

10' education - Nov. 14, 2022 - Pam Taub, MD, Prof. George Bakris, MD, and Prof. Gerasimos Filippatos, MD

A new option for cardiorenal protection for patients with CKD and T2DM

10' education - Nov. 14, 2022 - Prof. Gerasimos S. Filippatos, MD, Javier Morales, MD, and Angela Yee-Moon Wang, MD, PhD

Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD

3' education - Nov. 7, 2022 - David Preiss, PhD

Primary care as gatekeeper in CKD and the need for collaboration with nephrologists

10' education - July 13, 2022 - Prof. Kamlesh Khunti, MD, PhD

Discussion - Rethinking the role of nephrologists in prevention of CKD - The opportunity of early risk identification

10' education - July 6, 2022 - Prof. Christoph Wanner, MD, Rikke Borg, MD, PhD, and prof. Kamlesh Khunti, MD, PhD

Discussion - Preventing CKD in patients with diabetes - Exploring the current and future role of GLP-1RA

10' education - July 6, 2022 - Prof. Johannes Mann, MD, prof. Filip Knop, MD, PhD, and prof. Katherine Tuttle, MD

Why is early screening and risk identification of CKD in diabetes important?

10' education - July 6, 2022 - Rikke Borg, MD, PhD

Barriers for preventing CKD in patients with diabetes

10' education - June 28, 2022 - Prof. Christoph Wanner, MD

Which patients with CKD and diabetes will benefit from management with GLP-1RA?

10' education - June 13, 2022 - Prof. Katherine Tuttle, MD

What is relevant for nephrology with regard to GLP-1RA in CVD?

10' education - June 10, 2022 - Prof. Filip Knop, MD, PhD

Cardiorenal effects of nonsteroidal MRAs in patients with CKD and T2DM

10' education - June 7, 2022 - Eugene E. Wright, Jr., MD, Jolanta Małyszko, MD, PhD and María José Soler, MD, PhD

New insights and guidelines for the management of CKD and diabetes

10' education - May 31, 2022 - Prof. Johannes Mann, MD

Which patients benefit from potassium binders?

10' education - Feb. 15, 2022 - Kevin Damman, MD, PhD

Role of a non-steroidal MRA in the treatment spectrum of patients with T2DM and CKD

10' education - Feb. 8, 2022 - Prof. Peter Rossing, MD, prof. Gerasimos Filippatos, MD and prof. Matthew Weir, MD

Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

15' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

Dialogue on how to overcome clinical inertia with regard to SGLT2i

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

SGLT2i: Overview of recent trials and guideline recommendations

10' education - Oct. 28, 2021 - Prof. Nikolaus Marx, MD - Online CME

Introduction on tackling cardiorenal risk in diabetes

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD - Online CME

CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD

3' education - Aug. 28, 2021 - Kevin Damman, MD, PhD

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

How can GLP-1RA benefit a patient with diabetes and CKD?

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Prevention strategies in patients with CKD and T2DM

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Kidney benefit by SGLT2i may be mediated by hematocrit

5' education - June 14, 2021 - Prof. Christoph Wanner, MD

Head-to-head comparison of risk scores for ischemic stroke in patients with AF and CKD

5' education - June 14, 2001 - Ype de Jong, MD

Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction

10' education - May 11, 2021 - Prof. James Januzzi, MD

ASCVD history does not modify nonsteroidal MRA’s cardiorenal effects in T2DM and CKD

Literature - Nov. 29, 2022 - Filippatos G, et al. - Eur Heart J Cardiovasc Pharmacother. 2022

Irrespective of a history of ASCVD, finerenone reduced the risk of CV events and CKD progression compared with placebo in patients with T2DM and CKD, as shown in a FIDELITY subgroup analysis.

Beneficial effects of non-steroidal MRA on HF-related outcomes in CKD and T2DM

Literature - Nov. 22, 2022 - Filippatos G, et al. - JACC Heart Fail. 2022

Finerenone, a non-steroidal MRA, has been approved for the treatment of CKD in adults with T2DM. Previously, the FIDELITY study showed that finerenone improves cardiorenal outcomes in these patients. But does this also apply to HF-related outcomes?

Looking beyond diabetes: The role of SGLT2i and MRAs in cardiorenal disease

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD
Prof. Kosiborod reviews the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes in patients with heart failure and concomitant kidney dysfunction and/or diabetes.

Prof. Kosiborod reviews the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes in patients with heart failure and concomitant kidney dysfunction and/or diabetes.

New perspectives in managing heart failure and hyperkalemia – The cardiorenal angle

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD & Prof. Austin G. Stack, MD
RAASi therapy is a critical component of HF management; however, concern about patients developing hyperkalemia often leads to clinical delay and suboptimal dosing. Prof. Kosiborod and Prof Stack discuss how to manage hyperkalemia while continuing to up-titrate RAASi therapy in patients with HFrEF & CKD.

RAASi therapy is a critical component of HF management; however, concern about patients developing hyperkalemia often leads to clinical delay and suboptimal dosing. Prof. Kosiborod and Prof Stack discuss how to manage hyperkalemia while continuing to up-titrate RAASi therapy in patients with HFrEF & CKD.

Reducing morbidity and mortality in patients with CKD and T2DM

10' education - Nov. 14, 2022 - Pam Taub, MD, Prof. George Bakris, MD, and Prof. Gerasimos Filippatos, MD
The FIDELITY pooled analysis findings demonstrated benefits in CV and kidney outcomes with the nonsteroidal MRA finerenone. Pam Taub, Gerasimos Filippatos, and George Bakris discuss the risk factors of CKD, the importance of measuring eGFR and UACR, and how finerenone improves outcomes.

The FIDELITY pooled analysis findings demonstrated benefits in CV and kidney outcomes with the nonsteroidal MRA finerenone. Pam Taub, Gerasimos Filippatos, and George Bakris discuss the risk factors of CKD, the importance of measuring eGFR and UACR, and how finerenone improves outcomes.

A new option for cardiorenal protection for patients with CKD and T2DM

10' education - Nov. 14, 2022 - Prof. Gerasimos S. Filippatos, MD, Javier Morales, MD, and Angela Yee-Moon Wang, MD, PhD
Diabetic nephropathy is one of the leading causes of ESRD. Three experts explore recent data on the use of nonsteroidal MRAs and discuss how to prevent deterioration of renal function and improve CV outcomes across the spectrum of renal decline.

Diabetic nephropathy is one of the leading causes of ESRD. Three experts explore recent data on the use of nonsteroidal MRAs and discuss how to prevent deterioration of renal function and improve CV outcomes across the spectrum of renal decline.

Reduced worsening of kidney disease or CV death by SGLT2i in CKD patients

News - Nov. 7, 2022

AHA 2022 In the EMPA-KIDNEY trial, use of empagliflozin reduced the outcome of worsening of kidney disease or CV death compared with placebo in CKD patients. In addition, results of a meta-analysis of 13 SGLT2i trials in high-risk patients were presented.

Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD

3' education - Nov. 7, 2022 - David Preiss, PhD
David Preiss shares the results from the EMPA-KIDNEY trial and a collaborative meta-analysis including EMPA-KIDNEY and 12 other major SGLT2i trials.

AHA 2022 David Preiss shares the results from the EMPA-KIDNEY trial and a collaborative meta-analysis including EMPA-KIDNEY and 12 other major SGLT2i trials.

Effects of SGLT2i on renal function in patients hospitalized for acute HF

Literature - Oct. 17, 2022 - Voors AA, et al - Eur J Heart Fail. 2022

The EMPULSE trial showed that treatment with empagliflozin for 90 days results in a clinical benefit in patients hospitalized for acute HF, compared with placebo. Is this effect dependent on renal function? And what are the renal effects of empagliflozin in acute HF?

Insights into mechanism of action of SGLT2i in chronic HF using proteomics

Literature - Oct. 10, 2022 - Zannad F, et al. - Eur Heart J. 2022

By analysis of pooled plasma samples of 1134 patients from the EMPEROR-Reduced and EMPEROR-Preserved trials using large-scale proteomics, the authors identified several biological effects of empagliflozin on the heart and kidneys.

Inflammation stronger predictor of future MACE in statin-treated CKD patients than LDL-c

Literature - Sep. 25, 2022 - Ridker PM, et al. - Eur Heart J. 2022

Using data from the CANTOS trial, the investigators assessed the relative contributions of hyperlipidemia and inflammation to CV clinical outcomes in atherosclerosis patients on statin therapy, stratified by eGFR.

Effect of SGLT2i on shifts in KDIGO CKD risk groups in T2DM patients

News - Sep. 22, 2022

EASD 2022 A post-hoc analysis of EMPA-REG OUTCOME examined the effect of empagliflozin on changes in risk of progression to ESKD by assessing worsening and improvement in KDIGO risk groups.